Day: April 4, 2018

AGILeBiotics’ drug development is supported by the Versneller Innovatieve Ambities (VIA) – subsidy from Samenwerkingsverband Noord-Nederland (SNN)

Supported by the Versneller Innovatieve Ambities (VIA)-subsidy from Samenwerking Noord-Nederland (SNN), AGILeBiotics is developing novel antibiotics for hospital-treated Gram-negative infections. According to the World Health Organization (WHO) and the Infectious Disease Society of America (IDSA) the world is entering the post-antibiotic era, with no therapy option left for patients infected by multidrug-resistant (MDR) pathogen. Without novel […]